Alyeska Investment Group L.P. Has $3.32 Million Stake in Nkarta, Inc. (NASDAQ:NKTX)

Alyeska Investment Group L.P. raised its position in shares of Nkarta, Inc. (NASDAQ:NKTX - Free Report) by 23.0% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,334,696 shares of the company's stock after acquiring an additional 250,000 shares during the period. Alyeska Investment Group L.P. owned approximately 1.89% of Nkarta worth $3,323,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. JPMorgan Chase & Co. increased its stake in Nkarta by 138.7% during the fourth quarter. JPMorgan Chase & Co. now owns 2,537,922 shares of the company's stock valued at $6,319,000 after acquiring an additional 1,474,560 shares during the period. Wasatch Advisors LP increased its position in shares of Nkarta by 37.4% during the fourth quarter. Wasatch Advisors LP now owns 2,520,909 shares of the company's stock valued at $6,277,000 after purchasing an additional 686,229 shares during the period. Geode Capital Management LLC raised its stake in shares of Nkarta by 0.9% in the fourth quarter. Geode Capital Management LLC now owns 1,181,357 shares of the company's stock valued at $2,942,000 after purchasing an additional 10,331 shares in the last quarter. Affinity Asset Advisors LLC lifted its position in Nkarta by 23.1% in the fourth quarter. Affinity Asset Advisors LLC now owns 800,000 shares of the company's stock worth $1,992,000 after purchasing an additional 150,000 shares during the period. Finally, Dimensional Fund Advisors LP boosted its stake in Nkarta by 101.1% during the fourth quarter. Dimensional Fund Advisors LP now owns 569,357 shares of the company's stock worth $1,417,000 after buying an additional 286,181 shares in the last quarter. 80.54% of the stock is owned by institutional investors and hedge funds.

Nkarta Stock Down 0.3 %

NKTX stock traded down $0.01 during midday trading on Friday, reaching $1.95. 423,896 shares of the company's stock traded hands, compared to its average volume of 1,078,980. The company has a market cap of $138.01 million, a price-to-earnings ratio of -1.03 and a beta of 0.81. The company has a 50-day simple moving average of $1.78 and a two-hundred day simple moving average of $2.26. Nkarta, Inc. has a 1-year low of $1.31 and a 1-year high of $8.23.

Nkarta (NASDAQ:NKTX - Get Free Report) last issued its quarterly earnings results on Wednesday, March 26th. The company reported ($0.35) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.06. Equities research analysts forecast that Nkarta, Inc. will post -1.7 EPS for the current year.

Analyst Ratings Changes

NKTX has been the subject of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and set a $18.00 price objective on shares of Nkarta in a report on Thursday, March 27th. Needham & Company LLC reaffirmed a "buy" rating and set a $11.00 price objective on shares of Nkarta in a report on Wednesday, April 9th. Finally, Stifel Nicolaus dropped their target price on Nkarta from $15.00 to $14.00 and set a "buy" rating for the company in a report on Thursday, March 27th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and an average price target of $14.86.

Nkarta Company Profile

Nkarta, Inc, a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis.